Peptides vs Small-Molecule Drugs

Two very different chemical strategies

Roughly 40% of approved drugs in clinical pipelines right now are biologics or peptide-based , a stat I keep coming back to whenever someone asks me why peptide pharmacology is worth paying attention to. The short version is: the molecule category you're working with determines almost everything downstream. How it's absorbed, how the body breaks it down, how it reaches its target. None of that is incidental.

Small-molecule drugs and peptides are both used to interact with biological systems, but they do it through quite different chemical logic. Getting those differences straight is the foundation for understanding any of the more specific content on this site , whether that's pharmacokinetics, bioavailability, or how something like a GLP-1 receptor agonist ends up classified and regulated the way it does in Australia.

Defining the categories

A small-molecule drug is exactly what it sounds like: a low molecular weight compound, typically under 500 daltons. Most conventional pharmaceuticals fall here , aspirin, statins, beta-blockers. Their size lets them cross cell membranes relatively easily, which is part of why oral administration works for so many of them. The field has a shorthand rule of thumb called Lipinski's Rule of Five, published by Christopher Lipinski at Pfizer in 1997, which describes the physicochemical properties that make a small molecule orally bioavailable.

Peptides are chains of amino acids linked by peptide bonds. By convention, chains under about 50 amino acids are called peptides; longer ones become proteins (though that boundary is not rigid and researchers argue about it constantly). The molecular weights of therapeutic peptides typically sit between 500 and 5,000 daltons, sometimes higher. They're structurally more complex than most small molecules, and that complexity comes with both advantages and real pharmacological challenges.

The specificity trade-off

Here's where it gets interesting. Peptides evolved; literally, in a biological sense, to interact with receptors and enzymes with very high selectivity. They're shaped, often in three dimensions, to slot into specific binding sites in ways a smaller molecule simply can't replicate. That structural precision can mean a peptide engages its target with minimal off-target activity, at least in principle.

Small molecules can be extraordinarily specific too, and chemists have spent decades refining that. But they can also drift, binding to unintended receptor subtypes because the binding pocket looks similar. The history of drug development is littered with examples of small molecules pulled from market after off-target effects emerged post-approval. Peptides aren't immune to this, but their size and structural specificity do shift the risk profile somewhat.

Honestly, the cleaner specificity of peptides gets over-stated in popular science coverage. High selectivity in a cell assay doesn't always survive contact with a whole living organism. That's a real limitation in how early peptide research translates, and worth holding onto as a caveat whenever you read enthusiastic preclinical results.

Pharmacokinetics: where peptides pay a price

This is where the fundamental difference becomes most consequential from a drug-delivery standpoint, and it's the section I always find myself writing longest on.

Small molecules, because they're small and often lipophilic, can move across the gastrointestinal lining into systemic circulation. Oral bioavailability; the fraction of a dose that actually reaches circulation in active form, is achievable. Not guaranteed, and not always high. First-pass metabolism in the liver degrades many small molecules substantially, which is why dose, formulation, and route of administration are calibrated so carefully. But oral delivery is at least feasible for a large fraction of small-molecule drugs.

Peptides face a harder road. The gastrointestinal tract is, essentially, a peptide-destroying machine. Proteolytic enzymes in the stomach and small intestine, pepsin, trypsin, chymotrypsin and others; exist specifically to break peptide bonds so we can absorb amino acids as nutrients. A therapeutic peptide administered orally tends to get dismantled before it can do anything useful. On top of that, the GI epithelium doesn't transport large, hydrophilic molecules efficiently.

The result is that most therapeutic peptides are administered parenterally, injected. Subcutaneous injection is common, bypassing the GI tract entirely and allowing the peptide to absorb from the subcutaneous tissue into circulation. This is a real practical limitation. It constrains patient convenience and shapes how peptide-based products are formulated, packaged, and used.

I was actually rereading some of the pharmacokinetic literature on this during a long run last Sunday, one of those situations where the podcast in my ears stopped making sense because I got distracted working through the half-life maths. Occupational hazard.

Stability, half-life, and the proteolysis problem

Even once a peptide is in systemic circulation, it faces enzymatic degradation. Peptidases in the blood and tissues actively cleave peptide bonds; native (unmodified) peptides often have plasma half-lives measured in minutes. That's not workable for most therapeutic applications.

Pharmaceutical development has produced several strategies to address this. PEGylation; attaching polyethylene glycol chains, can extend half-life by increasing molecular size and reducing renal clearance. Incorporating non-natural amino acids (D-amino acids, which are mirror images of the L-amino acids our enzymes evolved to cleave) can make a peptide resistant to protease activity. Cyclisation, which forms a loop structure rather than a linear chain, similarly confers stability.

Small molecules don't face the same metabolic pressure from proteolysis, though they have their own metabolic liabilities, cytochrome P450 enzyme-mediated oxidation in the liver being the classic one. The point is that both classes require serious chemical engineering to be useful drugs; neither is naturally "ready to use" as found in nature.

Synthesis and manufacturing

Small molecules are generally synthesised through organic chemistry routes; multi-step reactions building the target compound from simpler precursors. The processes are well-understood, scalable, and the field has decades of manufacturing infrastructure behind it.

Peptides are assembled differently, most commonly via solid-phase peptide synthesis (SPPS), a method developed by Robert Bruce Merrifield in the 1960s that earned him a Nobel Prize in Chemistry in 1984. SPPS builds the amino acid chain stepwise on a solid resin support. The process works well for shorter peptides but becomes progressively more complex and lower-yielding for longer chains. Longer or more complex peptides are sometimes produced using recombinant biological expression systems instead.

The manufacturing complexity matters for regulatory purposes. In Australia, the Therapeutic Goods Administration requires that therapeutic goods, including peptide-based medicines, meet Good Manufacturing Practice standards, and products must be either listed or registered on the ARTG. Peptides marketed for performance enhancement or body composition are frequently unapproved goods in Australia, and supplying them without TGA approval is illegal under the Therapeutic Goods Act 1989. The TGA has been actively enforcing this. That regulatory reality shapes the entire landscape around peptide availability here in ways that small-molecule pharmaceuticals; with their longer regulatory history, don't face in quite the same way.

How they interact with biological targets

Small molecules typically target enzymes, ion channels, or receptors by fitting into a binding pocket, an active site or allosteric site, usually a defined cavity in the protein structure. Their small size means they can sometimes penetrate intracellular targets too, crossing membranes to act inside cells.

Peptides more often interact with the extracellular surface of receptors; particularly G-protein coupled receptors (GPCRs), receptor tyrosine kinases, and similar cell-surface targets. Their size makes intracellular delivery harder without specialised delivery systems, though this is an active area of research. Where they shine is in mimicking endogenous signalling molecules; many therapeutic peptides are analogues of hormones, neuropeptides, or cytokines that the body already uses. That biological mimicry is a significant part of their appeal.

It's worth noting that some of the most researched receptor systems in this space, GPCRs involved in metabolic and neurological signalling, overlap with areas of pharmacology we cover elsewhere on this site, including the endocannabinoid system and its constituent receptors. The CB1 receptor and CB2 receptor are both GPCRs, the same receptor family that many therapeutic peptides are designed to engage; which gives you a sense of how much of pharmacology converges on the same structural biology.

Where peptides sit in Australian regulation

A peptide medicine that has received TGA approval and is listed or registered on the ARTG may be accessed through normal prescription pathways, as a Schedule 4 (prescription only) medicine, for instance, depending on its classification under the Poisons Standard. Some are Schedule 8 controlled drugs. Others may be accessible under the TGA's Special Access Scheme or through an Authorised Prescriber arrangement, for goods that don't yet have full ARTG registration.

Unapproved peptides, those not on the ARTG and not accessed through a legitimate SAS or AP pathway; occupy a different space legally. Supplying them is illegal. This is not a grey area under current TGA enforcement policy, and the distinction between "approved therapeutic peptide" and "unapproved peptide product" is one that matters enormously in the Australian context.

The chemistry that makes peptides scientifically interesting doesn't change their regulatory status. Both things can be true at once.

Sources

• Peptides and Growth Factors, Therapeutic Goods Administration (TGA)
• Peptide Therapeutics: Current Status and Future Directions, NCBI / Drug Discovery Today
• Merrifield Solid-Phase Peptide Synthesis; NCBI Bookshelf
• Good Manufacturing Practice, Therapeutic Goods Administration (TGA)

, Priya Nandakumar, Pharmacology writer, peptides & PK